About
My academic journey began with a Ph.D. in Structural and Molecular Biology, awarded in 2007 from the University Paris VII Denis Diderot (now University Paris-Cité). I then completed two postdoctoral fellowships at INSERM and Généthon, before being recruited in 2015 as a Research Engineer at INSERM. In 2024, I obtained my Habilitation to Supervise Research (HDR) from University Paris-Cité, and was recently promoted to senior Research Engineer (hors classe).
As part of an international collaborative project, I was a visiting researcher at the University of Colorado – Anschutz Medical Campus in 2025, which strengthened my expertise in skin organoids and international scientific collaborations.
Since 2024, I have been an elected Board member of the French Society of Gene and Cell Therapy (SFTCG), actively contributing to the structuring and promotion of gene and cell therapy in France.
Scientific project
My work focuses on the development of clinically relevant genome editing strategies aimed at restoring the function of genes implicated in rare and severe skin disorders, particularly epidermolysis bullosa. My scientific expertise involves next-generation genome editing technologies, including CRISPR/Cas9, Base Editors, and Prime Editors, to correct recurrent COL7A1 mutations. This research addresses both fundamental questions, such as editing efficiency, specificity, and cellular consequences; and translational objectives, including the generation of corrected primary keratinocytes, fibroblasts, 3D skin equivalents and human: murine skin xenografts.
During a six-month international mobility program in 2024–2025 at the University of Colorado, I also developed expertise in the generation and characterization of iPSC-derived skin organoids. These advanced and physiologically relevant models are now being implemented in our laboratory as a versatile and scalable alternative to xenograft models, enabling the evaluation of genome editing efficacy and safety in combination with innovative delivery systems such as lipid nanoparticles (LNPs) and virus-like particles (VLPs), for future in vivo applications.
2020Journal (source)Expert Opin Emerg Drugs